Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
2019-nCoV Vaccine mRNA-1273
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Betacoronavirus
/ immunology
CD4 Antigens
COVID-19
COVID-19 Vaccines
Coronavirus Infections
/ immunology
Disease Models, Animal
Dose-Response Relationship, Immunologic
Immunization, Passive
Lung
/ pathology
Macaca mulatta
Pandemics
/ prevention & control
Pneumonia, Viral
/ immunology
SARS-CoV-2
Spike Glycoprotein, Coronavirus
T-Lymphocytes
/ immunology
Viral Load
Viral Vaccines
/ administration & dosage
Virus Replication
COVID-19 Serotherapy
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
pubmed:
30
7
2020
medline:
28
10
2020
entrez:
30
7
2020
Statut:
ppublish
Résumé
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.).
Sections du résumé
BACKGROUND
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates.
METHODS
Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens.
RESULTS
The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID
CONCLUSIONS
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.).
Identifiants
pubmed: 32722908
doi: 10.1056/NEJMoa2024671
pmc: PMC7449230
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
CD4 Antigens
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
spike protein, SARS-CoV-2
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1544-1555Subventions
Organisme : NIAID NIH HHS
ID : F32 AI152296
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007151
Pays : United States
Informations de copyright
Copyright © 2020 Massachusetts Medical Society.
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cell Rep. 2019 Sep 24;28(13):3395-3405.e6
pubmed: 31553909
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270
pubmed: 30420505
Sci Rep. 2016 Sep 29;6:34108
pubmed: 27682426
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nature. 2021 Feb;590(7844):E24
pubmed: 33469217
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Annu Rev Med. 2019 Jan 27;70:91-104
pubmed: 30691364
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
Curr Trop Med Rep. 2020;7(2):61-64
pubmed: 32219057
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
J Virol. 2018 Apr 27;92(10):
pubmed: 29514901
Emerg Microbes Infect. 2019;8(1):516-530
pubmed: 30938227
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11
pubmed: 30785039
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Biostatistics. 2014 Jan;15(1):87-101
pubmed: 23887981
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Emerg Microbes Infect. 2017 May 24;6(5):e37
pubmed: 28536429
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000
pubmed: 14569023
Nature. 2020 Mar;579(7800):482-483
pubmed: 32203366
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62
pubmed: 24043791
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Front Immunol. 2020 Jun 11;11:842
pubmed: 32595632
Cell. 2020 Aug 6;182(3):713-721.e9
pubmed: 32778225
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
J Exp Med. 2018 Jun 4;215(6):1571-1588
pubmed: 29739835
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Emerg Microbes Infect. 2016 Nov 9;5(11):e113
pubmed: 27826140
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Mol Ther. 2017 Jun 7;25(6):1316-1327
pubmed: 28457665
J Virol. 2017 Apr 28;91(10):
pubmed: 28275193
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Cytometry A. 2019 Mar;95(3):261-263
pubmed: 30681265
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544